Latest Vascular endothelial growth factor Stories

SAN DIEGO, May 20, 2013 /PRNewswire/ -- TRACON Pharmaceuticals, a biopharmaceutical company that develops targeted therapies for oncology and ophthalmology, today announced multiple clinical investigations for TRC105 and the presentation of two abstracts at the 49(th) Annual Meeting of the American Society of Clinical Oncology (ASCO), held May 31 to June 4 in Chicago. TRC105, a novel monoclonal antibody to endoglin (CD105), is being studied in multiple clinical trials in combination...

Findings suggest VEGF inhibition via TGF-B1 may be beneficial The most common cause of failure after glaucoma surgery is scarring at the surgical site, so researchers are actively looking for ways to minimize or prevent scar formation. Previous work had suggested that vascular endothelial growth factor (VEGF) activates fibrosis, whereas VEGF inhibition results in reduced scar formation and better surgical results. In a series of studies using a rabbit model of glaucoma surgery,...

ROCKVILLE, Md., May 15, 2013 /PRNewswire/ -- EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2013. (Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO ) The Company reported a net loss for the first quarter of approximately ($1.1 million), or ($0.05) per share, compared with a net loss of ($2.5 million), or ($0.23) per share, for the same period last year. The reported net loss...

Researchers at the University of California, San Diego School of Medicine and UC San Diego Moores Cancer Center report that cancers physically alter cells in the lymphatic system – a network of vessels that transports and stores immune cells throughout the body – to promote the spread of disease, a process called metastasis. The findings are published in this week's online Early Edition of the Proceedings of the National Academy of Sciences. Roughly 90 percent of all cancer deaths...

CAMBRIDGE, Mass., May 7, 2013 /PRNewswire/ -- The Angiogenesis Foundation released a white paper that addresses the barriers faced by individuals in the Asia-Pacific region in seeking effective treatment for wet Age-Related Macular Degeneration (AMD), the second-leading cause of blindness in the world. The white paper, "Wet Age-Related Macular Degeneration in the Asia-Pacific: Critical Pathways Forward," is the result of the Asia-Pacific Wet Age-Related Macular Degeneration Expert...

ROCKVILLE, Md., May 3, 2013 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced the issuance of a U.S. patent covering methods of treatment and formulations for its clinical-stage compound, 2-methoxyestradiol (2ME2). (Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO) Patent No. 8,399,440, entitled "Disease Modifying Anti-Arthritic Activity of 2-Methoxyestradiol,"...

'This study confirms that VEGF is not a path forward to tackling this disease' The well-studied protein VEGF does not appear to have any prognostic or predictive value for men with locally advanced prostate cancer, researchers from the Department of Radiation Oncology at Thomas Jefferson University Hospital and other institutions found in a retrospective study published online April 25 in the journal BMC Radiation Oncology. VEGF, or vascular endothelial growth factor, induces blood...

Scientific collaborators from Yale School of Medicine and University College London (UCL) have uncovered the molecular pathway by which new arteries may form after heart attacks, strokes and other acute illnesses bypassing arteries that are blocked. Their study appears in the April 29 issue of Developmental Cell. Arteries form in utero and during development, but can also form in adults when organs become deprived of oxygen — for example, after a heart attack. The organs release a...

A monoclonal antibody targeting a protein known as SFPR2 has been shown by researchers at the University of North Carolina to inhibit tumor growth in pre-clinical models of breast cancer and angiosarcoma. In a paper published in the April 19 issue of Molecular Cancer Therapeutics, a team led by Nancy Klauber-DeMore, MD, professor of surgery and a member of UNC Lineberger Comprehensive Cancer Center, used a monoclonal antibody to target SFRP2 expressed in cells from triple-negative breast...

DUBLIN, April 2, 2013 /PRNewswire/ -- Research and Markets) has announced the addition of the "Vascular Endothelial Growth Factor (VEGF) Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013" report to their offering      (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Vascular Endothelial Growth Factor (VEGF), which plays an important role in angiogenesis, has been extensively studied and over-expression is seen in many cancers. Today, VEGF is targeted using...